** Shares of Neurizon Therapeutics NUZ.AX rise 12% to A$0.14
* Stock hit highest level since Jan.20
** Biotech firm receives U.S. patent for NUZ-001 for treatment of neurodegenerative diseases
** Adds, patent grant follows FDA's Orphan Drug Designation for NUZ-001 in May 2024
** Stock down 26.5% this year as of last close
(Reporting by Sherin Sunny in Bengaluru)
((Sherin.Sunny@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.